The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 4D MOLECULAR THERAPEUTICS IN | COM | 35104E100 | 26,543 | 1,755,506 | SH | SOLE | 1,755,506 | 0 | 0 | ||
| AMRYT PHARMA PLC | SPONSORED ADS | 03217L106 | 13,563 | 1,640,000 | SH | SOLE | 1,640,000 | 0 | 0 | ||
| ARGENX SE | SPONSORED ADR | 04016X101 | 7,567 | 24,000 | SH | SOLE | 24,000 | 0 | 0 | ||
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 48,172 | 1,047,440 | SH | SOLE | 1,047,440 | 0 | 0 | ||
| ARVINAS INC | COM | 04335A105 | 46,790 | 695,247 | SH | SOLE | 695,247 | 0 | 0 | ||
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 49,925 | 781,539 | SH | SOLE | 781,539 | 0 | 0 | ||
| GENMAB A/S | SPONSORED ADS | 372303206 | 6,060 | 167,500 | SH | SOLE | 167,500 | 0 | 0 | ||
| MERUS N V | COM | N5749R100 | 33,355 | 1,261,534 | SH | SOLE | 1,261,534 | 0 | 0 | ||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 11,238 | 3,708,882 | SH | SOLE | 3,708,882 | 0 | 0 | ||
| REGENXBIO INC | COM | 75901B107 | 37,129 | 1,118,684 | SH | SOLE | 1,118,684 | 0 | 0 | ||
| SPDR S&P 500 ETF TR | UNIT | 78462F103 | 158,074 | 350,000 | SH | Put | SOLE | 0 | 0 | 350,000 | |
| SPDR S&P BIOTECH ETF TR | UNIT | 78464A870 | 179,760 | 2,000,000 | SH | Call | SOLE | 0 | 0 | 2,000,000 | |
| SPERO THERAPEUTICS INC | COM | 84833T103 | 45,949 | 5,281,504 | SH | SOLE | 5,281,504 | 0 | 0 | ||
| UNIQURE NV | SHS | N90064101 | 16,290 | 901,490 | SH | SOLE | 901,490 | 0 | 0 | ||